A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Hematocrit Levels at End of Initial Treatment Under Constant Dosing Regimen

Hematocrit (Hct) levels at end of initial treatment under constant dosing regimen were reported. Baseline (Day -28 to Day 1) Hct values was calculated as the mean of the SA (Week -3) and Run-in period (Weeks -2 and -1). For all participants, an EOIT value was calculated as the last observed Hct value before a dose change or blood transfusion. For participants without any dose adjustments, the EOIT value was identical to the value for Week 19.

Time frame: From Baseline (Day -28 to Day 1) to EOIT (Week 19)

Reticulocyte Count at End of Initial Treatment Under Constant Dosing Regimen

Reticulocyte levels at EOIT under constant dosing regimen was analysed and reported. Baseline (Day -28 to Day 1) reticulocyte values were calculated as the mean of the SA (Week -3) and Run-in period (Weeks -2 and -1). For all participants, an EOIT value was calculated as the last observed reticulocyte count before a dose change or blood transfusion. For participants without any dose adjustments, the EOIT value was identical to the value for Week 19.

Time frame: From Baseline (Day -28 to Day 1) to EOIT (Week 19)

Number of Participants With Any Serious Adverse Events and Any Adverse Events

An Adverse Events (AEs) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Events (SAEs) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes. The study design tested 3 different starting dose conversion factors at 3 different dosing schedules during the core study period. As study drug doses can be modified continually over time all results for the two long term safety periods were displayed by dose schedule group only.

Time frame: Up to Week 125

Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes Over Time

Marked abnormality was defined as above and/or below a value (according to the Roche specified limits) which was considered to be potentially clinically relevant. The Roche reference range are: white blood cells (WBC) (3.0-18.0 10\^9 cells/L), platelets (100-550 10\^9 cells/L), alanine aminotransferase (ALT) \[0-110 units per litre (U/L)\], alkaline phosphatase (ALP) (0-220 U/L), aspartate aminotransferase (AST) (0-80 U/L), albumin \>= 30 g/L, phosphate \[0.75 - 1.60 millimoles per liter (mmol/L)\], potassium (2.9 - 5.8 mmol/L), total bilirubin (0-17 µmol/L), lymphocytes (1- 4.80 10\^9 cells/L), eosinophils (0 - 0.45 10\^9 cells/L), monocytes (0 - 0.8 10\^9 cells/L), and neutrophils (1.80 - 7.70 10\^9 cells/L). The study design tested 3 different starting dose conversion factors at 3 different dosing schedules during the core study period. As study drug doses can be modified continually over time, all results for the two long term safety periods were displayed by dose schedule group only.

Time frame: Up to Week 125

Heart Rate Over Time

Heart rate was defined as the measure of heart beats per minute (bpm). The study design tested 3 different starting dose conversion factors at 3 different dosing schedules during the core study period. As study drug doses can be modified continually over time all results for the two long term safety periods were displayed by dose schedule group only.

Time frame: Up to Week 125

Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure

Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) is calculated as the end of treatment values minus the Baseline value. Baseline (Day -28 to Day 1) values were calculated as the mean of the SA (Week -3) and Run-in period (Week -2 and Week -1).

Time frame: From Baseline (Day -28 to Day 1) to Week 125